Biomedical subjects

David J Lunn

Publications and source records attributed to David J Lunn.

3 recordsLinked to original sources

PubMed2006

A Bayesian toolkit for genetic association studies.

We present a range of modelling components designed to facilitate Bayesian analysis of genetic-association-study data. A key feature of our approach is the ability to combine different submodels together, almost arbitrarily, for dealing with the complexities of real data. In particular, we propose various techniques for selecting the "best" subset of genetic predictors for a specific phenotype (or set of phenotypes). At the same time, we may control for complex, non-linear relationships between phenotypes and additional (non-genetic) covariates as well as accounting for any residual correlation that exists among multiple phenotypes. Both of these additional modelling components are shown to potentially aid in detecting the underlying genetic signal. We may also account for uncertainty regarding missing genotype data. Indeed, at the heart of our approach is a novel method for reconstructing unobserved haplotypes and/or inferring the values of missing genotypes. This can be deployed independently or, alternatively, it can be fully integrated into arbitrary genotype- or haplotype-based association models such that the missing data and the association model are "estimated" simultaneously. The impact of such simultaneous analysis on inferences drawn from the association model is shown to be potentially significant. Our modelling components are packaged as an "add-on" interface to the widely used WinBUGS software, which allows Markov chain Monte Carlo analysis of a wide range of statistical models. We illustrate their use with a series of increasingly complex analyses conducted on simulated data based on a real pharmacogenetic example.

Bayes Theorem↗

PubMed2003

Bayesian hierarchical approach to estimate insulin sensitivity by minimal model.

We adopted Bayesian analysis in combination with hierarchical (population) modelling to estimate simultaneously population and individual insulin sensitivity (SI) and glucose effectiveness (SG) with the minimal model of glucose kinetics using data collected during insulin-modified intravenous glucose tolerance test (IVGTT) and made comparison with the standard non-linear regression analysis. After fasting overnight, subjects with newly presenting Type II diabetes according to World Health Organization criteria (n =65; 53 males, 12 females; age, 54 +/- 9 years; body mass index, 30.4 +/- 5.2 kg/m2; means+/-S.D.) underwent IVGTT consisting of a 0.3 g of glucose bolus/kg of body weight given at time zero for 2 min, followed by 0.05 unit of insulin/kg of body weight at 20 min. Bayesian inference was carried out using vague prior distributions and log-normal distributions to guarantee non-negativity and, thus, physiological plausibility of model parameters and associated credible intervals. Bayesian analysis gave estimates of SI in all subjects. Non-linear regression analysis failed in four cases, where Bayesian analysis-derived SI was located in the lower quartile and was estimated with lower precision. The population means of SI and SG provided by Bayesian analysis and non-linear regression were identical, but the interquartile range given by Bayesian analysis was tighter by approx. 20% for SI and by approx. 15% for SG. Individual insulin sensitivities estimated by the two methods were highly correlated ( rS=0.98; P <0.001). However, the correlation in the lower 20% centile of the insulin-sensitivity range was significantly lower than the correlation in the upper 80% centile ( rS=0.71 compared with rS=0.99; P <0.001). We conclude that the Bayesian hierarchical analysis is an appealing method to estimate SI and SG, as it avoids parameter estimation failures, and should be considered when investigating insulin-resistant subjects.

Adult↗

PubMed2002

Bayesian analysis of population PK/PD models: general concepts and software.

Markov chain Monte Carlo (MCMC) techniques have revolutionized the field of Bayesian statistics by enabling posterior inference for arbitrarily complex models. The now widely used WinBUGS software has, over the years, made the methodology accessible to a great many applied scientists, in all fields of research. Despite this, serious application of MCMC methods within the field of population PK/PD has been comparatively limited. We appreciate that for many applied pharmacokineticists the prospect of conducting a Bayesian analysis will require numerous alien concepts to be taken on board and it may be difficult to justify investing the time and effort required in order to understand them (especially since the approach is so computer-intensive). For this reason we provide here a thorough (but often informal) discussion of all aspects of Bayesian inference as they apply specifically to population PK/PD. We also acknowledge that while the WinBUGS software is general purpose, model specification for some types of problem, population PK/PD being a prime example, can be very difficult, to the extent that a specialized interface for describing the problem at hand is often a practical necessity. In the latter part of this paper we describe such an interface, namely PKBugs. A principal aim of the paper is to offer sufficient technical background, in an easy to follow format, that the reader may develop both the confidence and know-how to make appropriate use of the PKBugs/WinBUGS framework (or similar software) for their own data analysis needs, should they choose to adopt a Bayesian approach.

Bayes Theorem↗